BridgeMD
Compares treatment options for Small Cell Lung Cancer
Official title A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT07155174
What this study is testing
What is ABBV-706?
ABBV-706 is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for small cell lung cancer.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is to assess safety, dose, change in disease activity of ABBV-706 given with atezolizumab, compared to standard of care (SOC) treatment (etoposide, carboplatin, atezolizumab, and optional lurbinectedin).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Diagnosis of histologically or cytologically confirmed extensive stage small cell lung cancer (ES-SCLC) requiring treatment with first line therapy.
- Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 during the screening period prior to the first dose of study treatment.
- Have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
- Suspected brain metastases at screening should have a computed tomography (CT)/ magnetic resonance imaging (MRI) of the brain prior to study entry.
You likely can't join if
- Have received any kind of treatment for limited stage small cell lung cancer (LS-SCLC).
- Known active/symptomatic central nervous system (CNS) metastases should be excluded.
- History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD/pneumonitis...
- Have any clinically significant conditions that would adversely affect the participant's participation in the study, and the subject should have a...
The study team makes the final eligibility decision.
Where it's taking place
- New Haven, Connecticut, United States
- Ocala, Florida, United States
- Tampa, Florida, United States
- Fort Wayne, Indiana, United States
- Lexington, Kentucky, United States
- Boston, Massachusetts, United States
- Columbia, Missouri, United States
- Cleveland, Ohio, United States
- Houston, Texas, United States
- Fairfax, Virginia, United States
- Charleroi, Hainaut, Belgium
- Liège, Liege, Belgium
- Hasselt, Limburg, Belgium
- Ghent, Oost-Vlaanderen, Belgium
- Beijing, Beijing Municipality, China
- Wuhan, Hubei, China
- Nanchang, Jiangxi, China
- Shanghai, Shanghai Municipality, China
- Immenhausen, Hesse, Germany
- Marburg, Hesse, Germany
+ 31 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Haven, Connecticut, United States; Ocala, Florida, United States; Tampa, Florida, United States; Fort Wayne, Indiana, United States; Lexington, Kentucky, United States; Boston, Massachusetts, United States and 45 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.